Molecular basis of mucopolysaccharidosis type II (Hunter syndrome): first review and classification of published IDS gene variants

被引:0
|
作者
Alessandra Zanetti [1 ]
Francesca D’Avanzo [2 ]
Rosella Tomanin [1 ]
机构
[1] Laboratory of Diagnosis and Therapy of Lysosomal Disorders, Department of Women’s and Children’s Health, University of Padova, Padova
[2] Fondazione Istituto di Ricerca Pediatrica Città della Speranza, Padova
关键词
Enzyme replacement therapy; Hunter syndrome; IDS; IDS variants; IDSP1; Iduronate; 2-sulfatase; Lysosomal storage disorder; MPS II; Mucopolysaccharidosis type II; Recombination; Variants classification;
D O I
10.1186/s40246-024-00701-w
中图分类号
学科分类号
摘要
Purpose: Mucopolysaccharidosis type II (MPS II) is a rare X-linked lysosomal storage disorder caused by genetic alterations in the iduronate 2-sulfatase (IDS) gene. A wide range of variants has been reported for different countries and ethnic groups. We collected, analyzed and uniformly summarized all published IDS gene variants reported in literature up to June 2023, here providing the first worldwide review and classification. Methods: Data was obtained from a literature search, conducted in PubMed and Google. All data was analyzed to define the most common alleles, geographic distribution and genotype-phenotype correlation. Moreover, point variants were classified according to their pathogenicity, based on the ACMG guidelines. Results: Several types of variants have been described in the IDS gene, including intrachromosomal homologous recombination occurring between the homologous regions of IDS gene and its pseudogene IDSP1. Overall, we collected 2852 individuals from 2798 families, including 24 female patients. Most families carried missense variants, followed by large deletions-insertions and complex rearrangements, small frameshift deletions/insertions and nonsense variants. Based on ACMG guidelines, 62.9% of the 779 point variants were classified as “pathogenic”, 35.4% as “likely pathogenic”, and the remaining 13 variants as having “uncertain significance”. Conclusion: Data from this study confirmed that MPS II is a genetically very heterogeneous disorder, making genotype-phenotype correlation very challenging and in most cases merely unfeasible. Mutation updates are essential for the correct molecular diagnosis, genetic counseling, prenatal and preimplantation diagnosis, and disease management. © The Author(s) 2024.
引用
收藏
相关论文
共 50 条
  • [1] Mucopolysaccharidosis type VI (MPS VI) and molecular analysis: Review and classification of published variants in the ARSB gene
    Tomanin, Rosella
    Karageorgos, Litsa
    Zanetti, Alessandra
    Al-Sayed, Moeenaldeen
    Bailey, Mitch
    Miller, Nicole
    Sakuraba, Hitoshi
    Hopwood, John J.
    HUMAN MUTATION, 2018, 39 (12) : 1788 - 1802
  • [2] Novel IDS Variants Identified in Three Unrelated Pakistani Patients Affected with Mucopolysaccharidosis Type II (Hunter Syndrome)
    Zubaida, Bibi
    Batool, Hajira
    Cheema, Huma Arshad
    Waheed, Nadia
    Naeem, Muhammad
    HUMAN HEREDITY, 2020, 84 (06) : 279 - 285
  • [3] Molecular basis of iduronate-2-sulphatase gene mutations in patients with mucopolysaccharidosis type II (Hunter syndrome)
    Li, PN
    Bellows, AB
    Thompson, JN
    JOURNAL OF MEDICAL GENETICS, 1999, 36 (01) : 21 - 27
  • [4] Molecular basis of mucopolysaccharidosis IVA (Morquio A syndrome): A review and classification of GALNS gene variants and reporting of 68 novel variants
    Zanetti, Alessandra
    D'Avanzo, Francesca
    AlSayed, Moeenaldeen
    Brusius-Facchin, Ana Carolina
    Chien, Yin-Hsiu
    Giugliani, Roberto
    Izzo, Emanuela
    Kasper, David C.
    Lin, Hsiang-Yu
    Lin, Shuan-Pei
    Pollard, Laura
    Singh, Akashdeep
    Tonin, Rodolfo
    Wood, Tim
    Morrone, Amelia
    Tomanin, Rosella
    HUMAN MUTATION, 2021, 42 (11) : 1384 - 1398
  • [5] Mucopolysaccharidosis Type II, Hunter's Syndrome
    Tylki-Szymanska, Anna
    PEDIATRIC ENDOCRINOLOGY REVIEWS PER, 2014, 12 : 107 - 113
  • [6] Mucopolysaccharidosis Type II (Hunter Syndrome): Clinical Picture and Treatment
    Beck, Michael
    CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2011, 12 (06) : 861 - 866
  • [7] Identification and Functional Characterization of IDS Gene Mutations Underlying Taiwanese Hunter Syndrome (Mucopolysaccharidosis Type II)
    Lin, Hsiang-Yu
    Tu, Ru-Yi
    Chern, Schu-Rern
    Lo, Yun-Ting
    Fran, Sisca
    Wei, Fang-Jie
    Huang, Sung-Fa
    Tsai, Shin-Yu
    Chang, Ya-Hui
    Lee, Chung-Lin
    Lin, Shuan-Pei
    Chuang, Chih-Kuang
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (01)
  • [8] Treatment of mucopolysaccharidosis type II (Hunter syndrome): results from a systematic evidence review
    Bradley, Linda A.
    Haddow, Hamish R. M.
    Palomaki, Glenn E.
    GENETICS IN MEDICINE, 2017, 19 (11) : 1187 - 1201
  • [9] Molecular diagnosis of 65 families with mucopolysaccharidosis type II (Hunter syndrome) characterized by 16 novel mutations in the IDS gene: Genetic, pathological, and structural studies on iduronate-2-sulfatase
    Kosuga, Motomichi
    Mashima, Ryuichi
    Hirakiyama, Asami
    Fuji, Naoko
    Kumagai, Tadayuki
    Seo, Joo-Hyun
    Nikaido, Mari
    Saito, Seiji
    Ohno, Kazuki
    Sakuraba, Hitoshi
    Okuyama, Torayuki
    MOLECULAR GENETICS AND METABOLISM, 2016, 118 (03) : 190 - 197
  • [10] Clinical, biochemical and molecular characteristics of Filipino patients with mucopolysaccharidosis type II - Hunter syndrome
    Chiong, Mary Anne D.
    Canson, Daffodil M.
    Abacan, Mary Ann R.
    Baluyot, Melissa Mae P.
    Cordero, Cynthia P.
    Silao, Catherine Lynn T.
    ORPHANET JOURNAL OF RARE DISEASES, 2017, 12